Form 4: Avalo Therapeutics CFO Sells Shares Under 10b5-1 Plan

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, has reported the sale of company stock through a pre-arranged trading plan.

Summary

• Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., reported transactions involving the sale of common stock.
• These sales occurred on April 1st and April 2nd, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025.
• A total of 500 shares were sold on April 1st at prices ranging from $15.24 to $16.21, leaving 32,797 shares.
• Additionally, 7,479 shares were sold on April 1st at prices ranging from $16.45 to $17.38, leaving 25,318 shares.
• On April 2nd, 6,200 shares were sold at prices between $16.385 and $17.37, resulting in 19,118 shares remaining.
• Further, 1,780 shares were sold on April 2nd at prices from $17.39 to $17.80, leaving 17,338 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by the CFO, even though it was conducted under a pre-arranged plan.

Negatives

• The Chief Financial Officer has sold a significant number of shares, indicating a potential lack of confidence or need for personal liquidity.

Risks

• The sale of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• The Rule 10b5-1 plan suggests a pre-determined strategy for selling shares, which may not reflect current company performance or outlook.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that insider selling, especially by C-suite executives, is a common event reported via Form 4 filings. While often executed under pre-arranged 10b5-1 plans to avoid insider trading concerns, significant sales can still influence market perception and signal potential shifts in executive confidence.

Stakeholder Impact

• Shareholders may view the CFO's stock sales with concern, potentially leading to short-term downward pressure on the stock price.
• Employees with stock options or grants may be affected by any negative market reaction to the insider selling.

Key Dates

Recommendation

The filing reports insider sales under a 10b5-1 plan, which is a routine event. While such sales can create short-term negative sentiment, they do not inherently provide enough information to warrant a strong buy or sell recommendation without further context on the company's fundamentals and future prospects.

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Stock Sale, Christopher Ryan Sullivan, CFO, Rule 10b5-1, Beneficial Ownership